Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.95 |
| ▸ | CPT2 | P23786 | 2/20 | 0.59 |
| ▸ | CPT1A | P50416 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | CRAT | P43155 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carnitine SCHEMBL1456180 | 1.00 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL4593172 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL21970 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| D-Carnitine SCHEMBL94286 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL17629811 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL3902633 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL21971 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL1813524 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL23249739 | 0.95 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL1456305 | 0.95 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239914-A1 | Phosphorus binder for treatment of renal disease | BIOLINK LIFE SCIENCES, INC. | 2009-09-24 | — | — | US | claimed |
| US-8093292-B2 | Conjugated fatty acid or alcohol, thiol-containing compound and bioavailable form of trivalent chromium; preventing metabolic dysregulation of adipocytes resulting from HIV-1 infection or chronic inflammation | BIONEXUS, LTD. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8034833-B2 | Phosphorus binder for treatment of renal disease | BIOLINK LIFE SCIENCES, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2170809-A2 | METHODS FOR THE PREPARATION AND FORMULATION OF L-CARNITINE VALPROATE SALTS | Biolink Life Sciences, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090239914-A1 | Phosphorus binder for treatment of renal disease | BIOLINK LIFE SCIENCES, INC. | 2009-09-24 | — | — | US | disclosed |
| CN-101400270-A | Composition for food and drink with improved hygroscopicity | SUNTORY LTD (JP) | 2009-04-01 | — | — | CN | disclosed |
| US-7456216-B2 | Methods for the preparation and formulation of l-carnitine valproate salts | BIOLINK LIFE SCIENCES, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| WO-2008116215-A2 | PHOSPHORUS BINDER FOR TREATMENT OF RENAL DISEASE | BIOLINK LIFE SCIENCES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234378-A1 | METHODS FOR THE PREPARATION AND FORMULATION OF L-CARNITINE VALPROATE SALTS | BIOLINK LIFE SCIENCES, INC. | 2008-09-25 | — | — | US | disclosed |
| WO-2008115920-A2 | METHODS FOR THE PREPARATION AND FORMULATION OF L-CARNITINE VALPROATE SALTS | BIOLINK LIFE SCIENCES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080114065-A1 | Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology | BIONEXUS, LTD. | 2008-05-15 | — | — | US | disclosed |
| US-7060295-B2 | Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus | CHRONORX LLC (US) | 2006-06-13 | — | — | US | disclosed |
| US-6693094-B2 | SUPPORTING MITOCHONDRIAL METABOLISM WITH A UNIT DOSAGE FORM OF CHOLINE, ASCORBATE, L-CARNITINE, MAGNESIUM, TAURINE, FOLIC ACID AND METFORMIN | CHRONO RX LLC | 2004-02-17 | — | — | US | disclosed |
| US-6689385-B2 | THERAPY FOR INSULIN RESISTANCE IN DIABETIC THERAPY | CHRONORX LLC | 2004-02-10 | — | — | US | disclosed |
| WO-2002059075-A1 | SALTS OF CARNITINES USEFUL AS DIETARY/NUTRITIONAL SUPPLEMENTS OR DRUGS, PROCESSES FOR PREPARING SAME AND COMPOSITIONS CONTAINING SUCH SALTS | FASSI, ALDO (IT) | 2002-08-01 | — | — | WO | disclosed |
| EP-0971879-B1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION COMPRISING L-CARNITINE AND ALKANOYL-L-CARNITINE MAGNESIUM TARTRATE | SIGMA TAU IND BR FARMACEUTICHE (IT) | 2001-11-14 | — | — | EP | disclosed |
| US-6130249-A | Solid compositions suitable for oral administration comprising L-carnitine and alkanoyl-L-carnitine magnesium tartrate | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-10-10 | — | — | US | disclosed |
| EP-0971879-A1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION COMPRISING L-CARNITINE AND ALKANOYL-L-CARNITINE MAGNESIUM TARTRATE | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045250-A1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION COMPRISING L-CARNITINE AND ALKANOYL-L-CARNITINE MAGNESIUM TARTRATE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239914-A1 | Phosphorus binder for treatment of renal disease | ALPI, PHPT1, FABP2 | SLC22A16 246/4885CPT2 3417/4885CPT1A 1258/4885 |
| US-20080234378-A1 | METHODS FOR THE PREPARATION AND FORMULATION OF L-CARNITINE VALPROATE SALTS | CPT1B, CPT1A, CRAT | SLC22A16 381/4885CPT2 4/4885CPT1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.